- Home
- DBL vs LRMR Comparison
DBL vs LRMR Comparison
Compare DBL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DBL | LRMR |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.3M | 316.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DBL | LRMR |
|---|---|---|
| Price | $15.25 | $3.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.71 |
| AVG Volume (30 Days) | 61.0K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.75 | $1.61 |
| 52 Week High | $15.70 | $5.37 |
Technical Indicators
Market Signals| Indicator | DBL | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 41.31 |
| Support Level | $15.14 | $3.31 |
| Resistance Level | $15.31 | $4.01 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 50.82 | 14.34 |
Price Performance
Historical ComparisonAbout DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.